Growing muscle has different sarcolemmal properties from adult muscle: A proposal with scientific and clinical implications: Reasons to reassess skeletal muscle molecular dynamics, cellular responses and suitability of experimental models of muscle disorders

BioEssays

Volumn 33, Issue 6, 2011, Pages 458-468

  Grounds, Miranda D ^a   Shavlakadze, Thea ^a  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

Growth; Muscular dystrophies; Myofibre elongation; Sarcolemma properties; Skeletal muscle

Indexed keywords

ARTICLE; HUMAN; MOLECULAR DYNAMICS; MUSCLE DEVELOPMENT; MUSCLE DISEASE; MUSCLE GROWTH; MUSCLE LENGTH; MYOPATHY; NONHUMAN; SARCOLEMMA;

ANIMALS; BONE DEVELOPMENT; DISEASE MODELS, ANIMAL; EXTRACELLULAR MATRIX; HUMANS; MUSCLE DEVELOPMENT; MUSCLE, SKELETAL; MUSCULAR DISEASES; MUSCULAR DYSTROPHIES, LIMB-GIRDLE; MUSCULAR DYSTROPHY, DUCHENNE; MYOFIBRILS; NECROSIS; SARCOLEMMA;

EID: 79956095344     PISSN: 02659247     EISSN: 15211878     Source Type: Journal    
DOI: 10.1002/bies.201000136     Document Type: Article

References (81)

1. Harris AJ, Duxson MJ, Butler JE, Hodges PW, et al. 2005. Muscle fiber and motor unit behavior in the longest human skeletal muscle. J Neurosci 25: 8528-33.
2. Paul AC. 2001. Muscle length affects the architecture and pattern of innervation differently in leg muscles of mouse, guinea pig, and rabbit compared to those of human and monkey muscles. Anat Rec 262: 301-9.
3. von der Hagen M, Laval SH, Cree LM, Haldane F, et al. 2005. The differential gene expression profiles of proximal and distal muscle groups are altered in pre-pathological dysferlin-deficient mice. Neuromuscul Disord 15: 863-77.
4. Shavlakadze T, Boswell JM, Burt DW, Asante EA, et al. 2006. Rskalphaactin/hIGF-1 transgenic mice with increased IGF-I in skeletal muscle and blood: impact on regeneration, denervation and muscular dystrophy. Growth Horm IGF Res 16: 157-73.
5. Bogin B. 2001. The Growth of Humanity. New York: Wiley-Liss. p. 319.
6. Stickland NC. 1981. Muscle development in the human fetus as exemplified by m. sartorius: a quantitative study. J Anat 132: 557-79.
7. Moore MJ, Rebeiz JJ, Holden M, Adams RD. 1971. Biometric analyses of normal skeletal muscle. Acta Neuropathol 19: 51-69.
8. Beilharz MW, Lareu RR, Garrett KL, Grounds MD, et al. 1992. Quantitation of muscle precursor cell activity in skeletal muscle by northern analysis of MyoD and myogenin expression - application to dystrophic (mdx) mouse muscle. Mol Cell Neurosci 3: 326-31.
9. White RB, Bierinx AS, Gnocchi VF, Zammit PS. 2010. Dynamics of muscle fibre growth during postnatal mouse development. MC Dev Biol 10: 21.
10. Fiorotto ML, Schwartz RJ, Delaughter MC. 2003. Persistent IGF-I overexpression in skeletal muscle transiently enhances DNA accretion and growth. FASEB J 17: 59-60.
11. Spalding KL, Bhardwaj RD, Buchholz BA, Druid H, et al. 2005. Retrospective birth dating of cells in humans. Cell 122: 133-43.
12. Ponsot E, Lexell J, Kadi F. 2008. Skeletal muscle telomere length is not impaired in healthy physically active old women and men. Muscle Nerve 37: 467-72.
13. Collins M, Renault V, Grobler LA, St Clair Gibson A, et al. 2003. Athletes with exercise-associated fatigue have abnormally short muscle DNA telomeres. Med Sci Sports Exerc 35: 1524-8.
14. McLoon LK, Thorstenson KM, Solomon A, Lewis MP. 2007. Myogenic precursor cells in craniofacial muscles. Oral Dis 13: 134-40.
15. Emery EH. 2002. The muscular dystrophies. Lancet 359: 687-95.
16. White JD, Vuocolo T, McDonagh M, Grounds MD, et al. 2008. Analysis of the callipyge phenotype through skeletal muscle development; association of Dlk1 with muscle precursor cells. Differentiation 76: 283-98.
17. Westerblad H, Bruton JD, Katz A. 2010. Skeletal muscle: energy metabolism, fiber types, fatigue and adaptability. Exp Cell Res 316: 3093-9.
18. Christov C, Chretien F, Abou-Khalil R, Bassez G, et al. 2007. Muscle satellite cells and endothelial cells: close neighbors and privileged partners. Mol Biol Cell 18: 1397-409.
19. Kjaer M. 2004. Role of extracellular matrix in adaptation of tendon and skeletal muscle to mechanical loading. Physiol Rev 84: 649-98.
20. Yurchenco PD, Patton BL. 2009. Developmental and pathogenic mechanisms of basement membrane assembly. Curr Pharm Design 15: 1277-94.
21. Grounds MD. 2008. Complexity of extracellular matrix and skeletal muscle regeneration. In Schiaffino S, Partridge TA, ed; Skeletal Muscle Repair and Regeneration. The Netherlands: Springer. p. 269-302.
22. Voermans NC, Bonnemann CG, Huijing PA, Hamel BC, et al. 2008. Clinical and molecular overlap between myopathies and inherited connective tissue diseases. Neuromuscul Disord 18: 843-56.
23. Grounds MD, Sorokin L, White J. 2005. Strength at the extracellular matrix-muscle interface. Scand J Med Sci Sports 15: 381-91.
24. Lapidos KA, Kakkar R, McNally EM. 2004. The dystrophin glycoprotein complex: signalling strength and integrity for the sarcolemma. Circ Res 94: 1023-31.
25. Jani K, Schock F. 2009. Molecular mechanisms of mechanosensing in muscle development. Dev Dyn 238: 1526-34.
26. Kanagawa M, Toda T. 2006. The genetic and molecular basis of muscular dystrophy: roles of cell-matrix linkage in the pathogenesis. J Hum Genet 51: 915-26.
27. Bozzi M, Morlacchi S, Bigotti MG, Sciandra F, et al. 2009. Functional diversity of dystroglycan. Matrix Biol 28: 179-87.
28. Lai FP, Mutalif RA, Phua SC, Stewart CL. 2010. Informatics-based analysis of mechanosignaling in the laminopathies. Methods Cell Biol 98: 323-35.
29. Hallmann R, Horn N, Selg M, Wendler O, et al. 2005. Expression and function of laminins in the embryonic and mature vasculature. Physiol Rev 85: 979-1000.
30. Hernandez L, Roux KJ, Wong ES, Mounkes LC, et al. 2010. Functional coupling between the extracellular matrix and nuclear lamina by Wnt signaling in progeria. Dev Cell 19: 413-25.
31. Serrano AL, Munoz-Canoves P. 2010. Regulation and dysregulation of fibrosis in skeletal muscle. Exp Cell Res 316: 3050-8.
32. Butler GS, Overall CM. 2009. Updated biological roles for matrix metalloproteinases and new "intracellular" substrates revealed by degradomics. Biochemistry 48: 10830-45.
33. Davis TA, Fiorotto ML. 2009. Regulation of muscle growth in neonates. Curr Opin Clin Nutr Metab Care 12: 78-85.
34. Suryawan A, Orellana RA, Fiorotto ML, Davis TA. 2010. Leucine acts as a nutrient signal to stimulate protein synthesis in neonatal pigs. J Anim Sci in press, DOI: 10.2527/jas.2010-3400.
35. Glass DJ. 2005. Skeletal muscle hypertrophy and atrophy signaling pathways. Int J Biochem Cell Biol 37: 1974-84.
36. Sandri M. 2008. Signaling in muscle atrophy and hypertrophy. Physiology (Bethesda) 23: 160-70.
37. Shavlakadze T, Chai J, Maley K, Cozens G, et al. 2010. A growth stimulus is needed for IGF-1 to induce skeletal muscle hypertrophy in vivo. J Cell Sci 123: 960-71.
38. Phillips SM. 2011. The science of muscle hypertrophy: making dietary protein count. Proc Nutr Soc 70: 100-3.
39. Raffaello A, Milan G, Masiero E, Carnio S, et al. 2010. JunB transcription factor maintains skeletal muscle mass and promotes hypertrophy. J Cell Biol 191: 101-13.
40. Chan S, Seto JT, Houweling PJ, Yang N, et al. 2010. Properties of extensor digitorum longus muscle and skinned fibers from adult and aged male and female Actn3 knockout mice. Muscle Nerve 43: 37-48.
41. Zammit PS, Partridge TA, Yablonka-Reuveni Z. 2006. The skeletal muscle satellite cell: the stem cell that came in from the cold. J Histochem Cytochem 54: 1177-91.
42. 2+ indicator FFP-18. Cell Calcium 40: 299-307.
43. Horwitz A, Schotland D. 1986. The plasma membrane of the muscle fiber. In Engel AG, Banker BQ, ed; Myology. USA: McGraw-Hill. p. 177-207.
44. Mayor S, Rao M. 2004. Rafts: scale-dependent, active lipid organization at the cell surface. Traffic 5: 231-40.
45. Draeger A, Monastyrskaya K, Burkhard FC, Wobus AM, et al. 2003. Membrane segregation and downregulation of raft markers during sarcolemmal differentiation in skeletal muscle cells. Dev Biol 262: 324-34.
46. Moral-Naranjo MT, Montenegro MF, Munoz-Delgado E, Campoy FJ, et al. 2010. The levels of both lipid rafts and raft-located acetylcholinesterase dimers increase in muscle of mice with muscular dystrophy by merosin deficiency. Biochim Biophys Acta 1802: 754-64.
47. Franzini-Armstrong C. 1991. Simultaneous maturation of transverse tubules and sarcoplasmic reticulum during muscle differentiation in the mouse. Dev Biol 146: 353-63.
48. Vigh L, Escriba PV, Sonnleitner A, Sonnleitner M, et al. 2005. The significance of lipid composition for membrane activity: new concepts and ways of assessing function. Prog Lipid Res 44: 303-44.
49. Schermelleh L, Heintzmann R, Leonhardt H. 2010. A guide to super resolution fluorescence microscopy. J Cell Biol 190: 165-75.
50. Brameshuber M, Weghuber J, Ruprecht V, Gombos I, et al. 2010. Imaging of mobile long-lived nanoplatforms in the live cell plasma membrane. J Biol Chem 285: 41765-71.
51. Owen DM, Magenau A, Majumdar A, Gaus K. 2010. Imaging membrane lipid order in whole, living vertebrate organisms. Biophys J 99: L7-9.
52. Han R, Campbell KP. 2007. Dysferlin and muscle membrane repair. Curr Opin Cell Biol 19: 409-16.
53. Lek A, Lek M, North KN, Cooper ST. 2010. Phylogenetic analysis of ferlin genes reveals ancient eukaryotic origins. BMC Evol Biol 10: 231.
54. Evesson FJ, Peat RA, Lek A, Brilot F, et al. 2010. Reduced plasma membrane expression of dysferlin mutants is attributed to accelerated endocytosis via a syntaxin-4-associated pathway. J Biol Chem 285: 28529-39.
55. Lo HP, Cooper ST, Evesson FJ, Seto JT, et al. 2008. Limb-girdle muscular dystrophy: diagnostic evaluation, frequency and clues to pathogenesis. Neuromuscul Disord 18: 34-44.
56. Cai C, Weisleder N, Ko JK, Komazaki S, et al. 2009. Membrane repair defects in muscular dystrophy are linked to altered interaction between MG53, caveolin-3, and dysferlin. J Biol Chem 284: 15894-902.
57. Noonan KJ, Farnum CE, Leiferman EM, Lampl M, et al. 2004. Growing pains: are they due to increased growth during recumbency as documented in a lamb model? J Pediatr Orthop 24: 726-31.
58. Grounds MD. 2008. Two-tiered hypotheses for Duchenne muscular dystrophy. Cell Mol Life Sci 65: 1621-5.
59. Biggar WD. 2006. Duchenne muscular dystrophy. Pediatr Rev 27: 83-8.
60. Quinlivan R, Shaw N, Bushby K. 2010. 170th ENMC International Workshop: bone protection for corticosteroid treated Duchenne muscular dystrophy. 27-29 November 2009, Naarden, The Netherlands. Neuromuscul Disord 20: 761-9.
61. Biggar WD, Harris VA, Eliasoph L, Alman B. 2006. Long-term benefits of deflazacort treatment for boys with Duchenne muscular dystrophy in their second decade. Neuromuscul Disord 16: 249-55.
62. Zatz M, Betti RT, Levy JA. 1981. Benign Duchenne muscular dystrophy in a patient with growth hormone deficiency. Am J Med Genet 10: 301-4.
63. Zatz M, Betti RT. 1986. Benign Duchenne muscular dystrophy in a patient with growth hormone deficiency: a five years follow-up. Am J Med Genet 24: 567-72.
64. Zatz M, Betti RT, Frota-Pessoa O. 1986. Treatment of Duchenne muscular dystrophy with growth hormone inhibitors. Am J Med Genet 24: 549-66.
65. Porter JD, Merriam AP, Khanna S, Andrade FH, et al. 2003. Constitutive properties, not molecular adaptations, mediate extraocular muscle sparing in dystrophic mdx mice. FASEB J 10: 893-901.
66. Zeiger U, Mitchell CH, Khurana TS. 2010. Superior calcium homeostasis of extraocular muscles. Exp Eye Res 91: 613-22.
67. Decary S, Hamida CB, Mouly V, Barbet JP, et al. 2000. Shorter telomeres in dystrophic muscle consistent with extensive regeneration in young children. Neuromuscul Disord 10: 113-20.
68. Sacco A, Mourkioti F, Tran R, Choi J, et al. 2010. Short telomeres and stem cell exhaustion model Duchenne muscular dystrophy in mdx/mTR mice. Cell 143: 1059-71.
69. Alexakis C, Partridge T, Bou-Gharios G. 2007. Implication of the satellite cell in dystrophic muscle fibrosis: a self-perpetuating mechanism of collagen overproduction. Am J Physiol Cell Physiol 293: C661-9.
70. Brack AS, Conboy MJ, Roy S, Lee M, et al. 2007. Increased Wnt signalling during aging alters muscle stem cell fate and increases fibrosis. Science 317: 807-10.
71. Albrecht DE, Garg N, Rufibach LE, Williams BA, et al. 2009. 3rd Annual Dysferlin Conference 2-5 June 2009, Boston, Massachusetts, USA. Neuromuscul Disord 19: 867-73.
72. th Annual Dysferlin Conference 11-14 September 2010, Washington, USA. Neuromuscul Disord 21: 304-10.
73. Shavlakadze T, Grounds MD. 2003. Therapeutic interventions for age related muscle wasting: importance of innervation and exercise for preventing sarcopenia. In Rattan S, ed; Modulating Aging and Longevity. Singapore: Kluwer Academic Publisher. p. 139-66.
74. Cruz-Jentoft AJ, Baeyens JP, Bauer JM, Boirie Y, et al. 2010. Sarcopenia: European consensus on definition and diagnosis: Report of the European Working Group on Sarcopenia in Older People. Age Ageing 39: 412-23.
75. Chan S, Head SI. 2010. Age- and gender-related changes in contractile properties of non-atrophied EDL muscle. PLoS One 5: e12345.
76. Sayer AA, Syddall H, Martin H, Patel H, et al. 2008. The developmental origins of sarcopenia. J Nutr Health Aging 12: 427-32.
77. Patel H, Jameson K, Syddall H, Martin H, et al. 2011. Developmental influences, muscle morphology and sarcopenia in community dwelling older men. J Gerontol A Biol Sci Med Sci, in press, DOI: 10.1093/gerona/glr020.
78. Bogin B. 1999. Patterns of Human Growth. Cambridge: Cambridge University Press. p. 455.
79. Grounds MD, Radley HG, Lynch GS, Nagaraju K, et al. 2008. Towards developing standard operating procedures for pre-clinical testing in the mdx mouse model of Duchenne muscular dystrophy. Neurobiol Dis 31: 1-19.
80. Willmann R, Possekel S, Dubach-Powell J, Meier T, et al. 2009. Mammalian animal models for Duchenne muscular dystrophy. Neuromuscul Disord 19: 241-9.
81. Smith BF, Yue Y, Woods PR, Kornegay JN, et al. 2011. An intronic LINE-1 element insertion in the dystrophin gene aborts dystrophin expression and results in Duchenne-like muscular dystrophy in the corgi breed. Lab Invest 91: 216-31.